Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote & News

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 659 8001

Website: www.rocketpharma.com

Address:

9 Cedarbrook Drive, Cranbury, United States

DiamondHandsHarold Aug. 19 at 6:30 PM

$RCKT

0 · Reply

Resilience1239 Aug. 19 at 5:58 PM

$RCKT RCKT is 95% institutionally owned....... Market doesn't care what the average people think... When ever the 95% decide they want this to run, it'll run, until then nothing matters, not even news or results. True Story.

0 · Reply

TheGodsMustBeCrazy Aug. 19 at 3:06 PM

$RCKT the market still has not properly understood how important the recent safety update was of those three new patients. As people realize how extremely important that update was, the stock will run.

1 · Reply

TheGodsMustBeCrazy Aug. 19 at 3:04 PM

$RCKT

0 · Reply

quickaspeter Aug. 19 at 2:47 PM

$RCKT 🎯 I like your thinking…💥🚀💰💰

1 · Reply

alotobeer Aug. 19 at 2:32 PM

$RCKT well this was a nice surprise

0 · Reply

Risk1123 Aug. 18 at 7:51 PM

$RCKT biggest thing for me is the Danon program and what the FDA says about moving forward with more patients

0 · Reply

DiamondHandsHarold Aug. 18 at 6:00 PM

$RCKT

0 · Reply

Magnificent77 Aug. 18 at 1:06 PM

$RCKT prime buyout looking company??👀

1 · Reply

Prazzclatt Aug. 17 at 8:30 PM

$RCKT The latest Danon safety update was encouraging. All three initial patients cleared the observation period without the major safety issues they were watching for

0 · Reply

Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush

2026-08-10T20:05:45.000Z - 8 days ago

Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c

Aug 10, 2026, 4:00 PM EDT - 8 days ago

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Rocket Pharmaceuticals Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Rocket Pharmaceuticals Earnings release: Q2 2026

2026-08-03T11:05:58.000Z - 16 days ago

Rocket announces safety update from three patients treated with RP-A501

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

2026-06-12T11:05:45.000Z - 2 months ago

Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M

Jun 12, 2026, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:10 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T15:27:07.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

May 28, 2026, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 20, 2026, 9:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Transcript: AGM 2026

2026-05-07T21:49:50.000Z - 3 months ago

Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

May 7, 2026, 4:00 PM EDT - 3 months ago

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Earnings release: Q1 2026

2026-04-28T11:29:11.000Z - 4 months ago

Rocket Pharmaceuticals announces $180M sale of priority review voucher

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

2026-03-30T10:30:11.000Z - 5 months ago

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

2026-03-27T19:15:17.000Z - 5 months ago

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

2026-03-27T16:13:26.000Z - 5 months ago

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

2026-03-27T16:10:33.000Z - 5 months ago

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Rocket Pharmaceuticals Transcript: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Rocket Pharmaceuticals Press release: FDA announcement

Mar 27, 2026, 7:27 AM EDT - 5 months ago

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

2026-03-27T11:05:10.000Z - 5 months ago

Rocket Pharmaceuticals announces FDA approval of Kresladi

Mar 27, 2026, 7:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

2026-03-27T00:55:09.000Z - 5 months ago

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

2026-03-10T21:40:14.000Z - 5 months ago

Rocket Pharmaceuticals offers to sell up to $100M in common stock

Mar 10, 2026, 9:20 AM EDT - 5 months ago

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-02T21:21:06.000Z - 6 months ago

Rocket Pharmaceuticals files $400M mixed securities shelf

Mar 2, 2026, 11:10 AM EST - 6 months ago

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals Registration statement: Registration Filing

2026-03-02T11:54:20.000Z - 6 months ago

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

2026-02-27T15:05:34.000Z - 6 months ago

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

Feb 26, 2026, 4:00 PM EST - 6 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Feb 26, 2026, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals Annual report: Q4 2025

Jan 14, 2026, 2:15 PM EST - 7 months ago

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 8 months ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 7:55 AM EST - 9 months ago

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:00 AM EST - 9 months ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 4:00 PM EST - 10 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rocket Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rocket Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rocket Pharmaceuticals Slides: Corporate Presentation

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 10, 2025, 4:00 PM EDT - 11 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 7:11 AM EDT - 11 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Sep 9, 2025, 9:15 AM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 3:20 PM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 11:02 AM EDT - 1 year ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 7:09 AM EDT - 1 year ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 8, 2025, 2:16 PM EDT - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Quarterly report: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 9, 2025, 5:16 PM EDT - 1 year ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

DiamondHandsHarold Aug. 19 at 6:30 PM

$RCKT

0 · Reply

Resilience1239 Aug. 19 at 5:58 PM

0 · Reply

TheGodsMustBeCrazy Aug. 19 at 3:06 PM

1 · Reply

TheGodsMustBeCrazy Aug. 19 at 3:04 PM

$RCKT

0 · Reply

quickaspeter Aug. 19 at 2:47 PM

$RCKT 🎯 I like your thinking…💥🚀💰💰

1 · Reply

alotobeer Aug. 19 at 2:32 PM

$RCKT well this was a nice surprise

0 · Reply

Risk1123 Aug. 18 at 7:51 PM

$RCKT biggest thing for me is the Danon program and what the FDA says about moving forward with more patients

0 · Reply

DiamondHandsHarold Aug. 18 at 6:00 PM

$RCKT

0 · Reply

Magnificent77 Aug. 18 at 1:06 PM

$RCKT prime buyout looking company??👀

1 · Reply

Prazzclatt Aug. 17 at 8:30 PM

$RCKT The latest Danon safety update was encouraging. All three initial patients cleared the observation period without the major safety issues they were watching for

0 · Reply

DiamondHandsHarold Aug. 17 at 2:10 PM

$RCKT

0 · Reply